iShares Core MSCI EAFE ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? iShares Core MSCI EAFE ETF trades at $96.27 (market cap $189.19B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.84 (market cap $6.04B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 31.3× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| IEFA | IOVA | |
|---|---|---|
Market Cap | $189.19B | $6.04B |
Volume | 8,441,787 | 14,805,993 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $14.82 |
52-Week Low | $85.06 | $1.81 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $5.97B |
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →